ArticleEuropean child & adolescent psychiatry2026
Prescriber-recorded indications for antipsychotic use in children and adolescents in Spain, 2015-2023: a population-based, real-world study.
Article in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in antipsychotic drug utilisation and indication in the paediatric population: a nationwide cohort study in Sweden.BMJ mental health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The use of antipsychotics (APs) in children and adolescents has increased notably worldwide, often beyond approved indications. However, most real-world studies lack direct information on the clinical reasons for prescribing. In this population-based study conducted in the region of Valencia, Spain, we analysed 128,057 AP treatments, comprising 741,213 prescriptions, issued to 30,383 individuals aged 0-19 years between 2015 and 2023, using real-world data that uniquely includes prescriber-recorded indications. We described the distribution and temporal evolution of the number of AP treatments by indication, age, sex, and active substance. The most frequent indications were disorders of personality and behaviour (20.2% of treatments), attention-deficit/hyperactivity disorder (14.2%), autism spectrum disorders (13.9%), anxiety-related disorders (11.4%), and psychotic disorders (5.8%). Among the most frequent indications, depression treatments showed the steepest increase (5.7-fold). Sharp rises also were observed for suicidal ideation (30.7-fold), psychoactive drug use (2.8-fold), eating disorders (2.3-fold), and autism-related conditions (2.2-fold). Changes were more pronounced in females and older adolescents, particularly after 2020. The number of ADHD treatments declined substantially over time. Sulpiride was almost exclusively prescribed for dizziness, a non-psychiatric but approved indication in adults in Spain. Our findings align with international trends but provide greater specificity thanks to the direct link between prescriptions and indications. This study highlights an increase in the volume of AP treatments in paediatric populations, mostly in non-approved, and potentially high-risk indications, some of which have not been previously documented. Our results underscore the need for close monitoring and further evaluation of the appropriateness and safety of antipsychotic prescription in the youth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.